Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for STRO-002 Antibody-Drug Conjugate Program for Treatment of Advanced Ovarian Cancer


– Dr. Naumann and Sutro’s management to discuss interim data for the STRO-002 Phase 1 Dose Expansion Cohort at a company event scheduled for Wednesday, January 5, 2022 at 5 p.m. ET or 2 p.m. PT

SOUTH SAN FRANCISCO, California, Dec. 27 2021 / PRNewswire / – Sutro Biopharma, Inc. (“Sutro”), (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and of a rational design to create next-generation cancer and autoimmune therapeutics, today announced that it will provide interim data from the Company’s ongoing dose expansion cohort for the Phase 1 study of STRO-002, an alpha folate receptor (FolRα) targeting the antibody-drug conjugate (ADC), for patients with ovarian cancer, at a virtual KOL event hosted by the company. The event and question-and-answer session will be available via webcast, to be held on Wednesday 5 January 2022, at 5 p.m. ET, Where 2 p.m. PT.

The phase 1 dose extension cohort includes patients with advanced ovarian cancer with progressive disease, who had previously received up to three lines of treatment, and is open to patients who have not were selected on the basis of the expression of FolRα. The study had a target enrollment of 40 patients, with the first patient receiving January 2021 and completed recruitment with 44 patients in November 2021.

The data will be presented by the management of Sutro and Dr R. Wendel Naumann, principal investigator in studies STRO-002-GM1. Dr Naumann is Professor and Director of Research in Gynecologic Oncology and Associate Medical Director of Clinical Trials at the Levine Cancer Institute, Atrium Health at Charlotte, North Carolina. Dr Naumann is also a member of the Sutro Clinical Advisory Committee.

Information on the virtual event of the company KOL:

The webcast and login information will also be available through the Investor Relations News and Events page on the Company’s website at An archived replay will be available for at least 30 days after the event.

About the STRO-002-GM1 Phase 1 Clinical Trial
STRO-002-GM1 is a Phase 1 trial for STRO-002 for patients with advanced ovarian cancer and endometrial cancer who have progressed or relapsed after standard treatments, in order to assess efficacy, safety and tolerance. The Ovarian Cancer Dose Escalation Cohort has completed recruitment. The ovarian cancer dose extension cohort has completed recruitment and the study is ongoing, with participation from clinical sites in the United States and Spain. The study includes all FolRα expression levels and a tissue sample from each patient is required for biomarker analysis. Patients in the dose extension cohort are randomized 1: 1 to receive 4.3 or 5.2 mg / kg STRO-002 and treated every three weeks.

About Sutro Biopharma
Sutro Biopharma, Inc., located at South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro advances next-generation oncology therapies.

The proprietary and integrated XpressCF® cell-free protein synthesis platform and the XpressCF + â„¢ site-specific conjugation platform led to the discovery of STRO-001 and STRO-002, the first two ADCs developed in-house by Sutro . STRO-001 is a CD74-targeting ADC currently under investigation in a Phase 1 clinical trial for patients with advanced B-cell malignancies and has received orphan drug designation from the FDA for multiple myeloma. STRO-002, an ADC targeting the alpha folate receptor (FolRα), is currently under investigation in a Phase 1 clinical trial for patients with ovarian and endometrial cancer and has been designated Fast FDA Tracker for Ovarian Cancer. A third product candidate, CC-99712, an ADC targeting BCMA, which is part of Sutro’s collaboration with Bristol Myers Squibb, formerly Celgene Corporation, is recruiting patients for its Phase 1 clinical trial in patients with multiple myeloma and has received the orphan drug designation. from the FDA. A fourth product candidate, M1231, a first-in-class bispecific MUC1-EGFR ADC, which is part of Sutro’s collaboration with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the United States and Canada (EMD Serono), is recruiting patients for its Phase 1 clinical trial in patients with metastatic solid tumors, non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the esophagus. These four product candidates are from Sutro’s XpressCF® and XpressCF + â„¢ technology platforms. Bristol Myers Squibb and EMD Serono have worldwide development and commercialization rights for CC-99712 and M1231, respectively, for which Sutro is entitled to milestone or conditional payments and milestone royalties.

Sutro is dedicated to transforming the lives of cancer patients by creating drugs with improved treatment profiles for areas where needs are unmet. To date, Sutro’s platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines against previous targets in clinical indications where the current standard of care is under- optimal.

The platform enables him to accelerate the discovery and development of potential first-class and first-class molecules through rapid and systematic evaluation of structure-activity relationships of proteins to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro collaborates with selected pharmaceutical and biotechnology companies to discover and develop new next-generation therapies.

Follow Sutro on Twitter, @Sutrobio, and to to learn more about our passion for changing the future of oncology.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, planned preclinical and clinical development activities, timing announcements of clinical results, the benefits of the Company’s product candidates and platform, potential future milestone and royalty payments, and potential market opportunities for the Company’s product candidates. All statements other than statements of historical fact are statements which could be considered as forward-looking statements. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of the development of biotechnology and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ materially from those expressed in any forward-looking statement, including risks and uncertainties relating to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the impact of the COVID-19 pandemic on the Company’s business, clinical trial sites , the supply chain and manufacturing facilities, the Company’s ability to maintain and recognize the benefits of certain nominations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and to achieve the development objectives, the capacity of the Company é to protect the intellectual property, the value of the ordinary shares of Vaxcyte held by the Company and the Company’s commercial collaborations with third parties and other r risks and uncertainties described under the heading “Risk factors” in the documents that the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances subsequent to the date hereof.

Investor contact
Annie j chang
Sutro Biopharma
(650) 801-5728
[email protected]

Media contact
Maggie Beller
Russian partners
(646) 942-5631
[email protected]


Show original content: stro-002-for-advanced-ovarian-cancer-treatment-301450821.html

SOURCE Sutro Biopharma


Comments are closed.